Patent: 10,088,479
✉ Email this page to a colleague
Summary for Patent: 10,088,479
Title: | Biomarker and uses thereof |
Abstract: | The invention relates to a method of determining the inflammatory disorder status of a subject comprising detecting the presence or absence, or the level, of (i) citrullinated tenascin-C and/or one or more fragments of citrullinated tenascin-C; and/or (ii) autoantibodies with specificity for citrullinated tenascin-C and/or one or more fragments of citrullinated tenascin-C, in a sample from said subject. |
Inventor(s): | Midwood; Kim Suzanne (Headington, GB), Venables; Patrick John (Headington, GB) |
Assignee: | OXFORD UNIVERSITY INNOVATION LIMITED (Oxford, GB) |
Application Number: | 15/109,775 |
Patent Claims: | see list of patent claims |
Details for Patent 10,088,479
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2034-01-13 |
Bristol-myers Squibb Company | ORENCIA | abatacept | For Injection | 125118 | 12/23/2005 | ⤷ Try a Trial | 2034-01-13 |
Bristol-myers Squibb Company | ORENCIA | abatacept | Injection | 125118 | 07/29/2011 | ⤷ Try a Trial | 2034-01-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |